CAR T-cell therapy is one of the most sophisticated tools in modern oncology, but it suffers from a persistent, frustrating flaw: it often stops working too soon. While the treatment can induce remission in patients with difficult-to-treat blood cancers, most experience a relapse within five years. Now, researchers at the University of Maryland School of Medicine (UMSOM) may have found the reason why these engineered immune cells lose their edge.

In a study published in Signal Transduction and Targeted Therapy, scientists discovered that CAR T-cells often engage in a self-defeating behavior. As they encounter tumor cells, they don't just attack; they physically tear off fragments of the cancer cell's surface and incorporate them into their own membranes. This process, which the researchers call "trogocytosis," effectively blunts the immune cells' ability to recognize and destroy their targets.

The Mechanism of Immune Exhaustion

To understand this phenomenon, the team utilized lattice light sheet microscopy, an advanced imaging technique that allowed them to watch the interaction between immune cells and tumors in real-time. They observed the CAR T-cells literally ripping pieces of the cancer cell surface away.

"This process makes the CAR T-cells less effective at attacking cancer," said Dr. Tim Luetkens, associate professor of microbiology and immunology at UMSOM and senior author of the study. The researchers identified a specific protein, cathepsin B, as the primary driver of this destructive behavior. When the team blocked cathepsin B in lab and animal models, the CAR T-cells stopped tearing off tumor fragments. Consequently, they remained active for longer periods and demonstrated significantly higher tumor-fighting efficacy.

Why This Matters for Clinical Outcomes

For patients with recurrent B-cell lymphoma, the durability of CAR T-cell therapy is the difference between long-term survival and a return to treatment. Current therapies often fail because the engineered cells become "exhausted" or lose their target specificity. By preventing the uptake of tumor surface fragments, researchers hope to keep these cells in a "primed" state, ready to continue their work long after the initial infusion.

"While these findings need to be translated into human clinical trials, this is real progress that could ultimately improve durability and outcomes for our patients," said Dr. Taofeek K. Owonikoko, executive director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. The center is already conducting a first-in-human clinical trial for B-cell lymphoma, providing a potential pipeline for testing these new insights.

What Experts Say

Researchers emphasize that while the findings are promising, the transition from animal models to human patients is complex. The goal is to refine the genetic engineering process so that the T-cells are modified to block cathepsin B without compromising their other essential functions.

"Scientists are still figuring out how these cells work and how to make them better," Dr. Luetkens noted. The next phase of research will focus on whether this protein inhibition can be safely integrated into the manufacturing process for clinical-grade CAR T-cells without causing unforeseen toxicity.

Key Takeaways

  • The Problem: CAR T-cells often "tear" pieces of tumor cells, which reduces their ability to effectively target and kill cancer.
  • The Discovery: Researchers identified the protein cathepsin B as the key driver of this process.
  • The Potential: Blocking cathepsin B in lab models kept immune cells active longer, suggesting a path to more durable cancer treatments.

As the UMSOM team moves toward potential clinical applications, the focus will shift to whether this molecular "brake" can be safely removed in human patients. The success of this approach will likely be measured by the duration of patient remissions in upcoming trials, with data expected to emerge as the current clinical studies progress over the next 18 to 24 months.

This article is for informational purposes only. Always consult a qualified healthcare professional before making any medical decisions.